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Abstract 
Cannabis is the most commonly used illicit substance in the world (United Nations Office on 
Drugs and Crime, 2018). Despite past criminalization, various states have begun to decriminalize 
cannabis for recreational and medical use; however, research on the effect of cannabis use on 
mental health is divided. Research on specific mental health disorders, like generalized anxiety 
disorder (GAD), and cannabis use is lacking. This study aimed to understand whether cannabis 
use affected individuals likelihood of meeting criteria for GAD by using a nationally 
representative longitudinal dataset. Results indicated that the inclusion of cannabis use did not 
explain additional variability in meeting criteria for GAD, suggesting that the relationship 
between GAD and cannabis use is not a straightforward causal relationship. Secondary analysis 
indicated history of anxiety or mood disorder and seeking mental health were significant 
predictors at all levels of GAD. Findings highlight the need to further explore the etiology of 
cannabis use and GAD.  
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Changes in Cannabis Use as a Predictor of Generalized Anxiety Disorder 
Introduction  
Cannabis has consistently been the most commonly used illicit drug in the United States 
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2018a) and the world 
(United Nations Office on Drugs and Crime, 2018). A comparison of drug use incidence in the 
United States revealed an increase in users who reported using cannabis in the past year, from 
10.88% in 2008-2009 to 14.5% in 2016-2017 (SAMHSA, 2018b). Similarly, SAMHSA (2018a) 
estimated that cannabis use increased among all individuals over the age of 12 in the United 
States, up to 40 million users in 2017 from 37 million users in 2016. The greatest increase in new 
cannabis users was observed in the 12-25 age group, which yielded 667 million new users in this 
timeframe (SAMHSA, 2018a). These substantial increases in new cannabis users were likely 
reflective of recent political shifts in the United States. At the time of writing, 33 states and 3 
territories had legalized medicinal cannabis, with 14 of those states also legalizing recreational 
use of cannabis (National Conference of State Legislatures, 2019). Problematically, the field of 
psychology is divided regarding the effect of cannabis use on individuals’ psychiatric symptoms 
and its efficacy as a form of treatment.  
Using cannabis for medicinal purposes has been traced back to 2000 BCE when it was 
described in the earliest Chinese pharmacopeia for various ailments ranging from nausea to 
scorpion stings (Newton, 2017). Cannabis was not formally presented as a modern medicine in 
Europe until 1839, when it was recommended for treating muscle spasms, vomiting and diarrhea. 
Soon after, in 1850, it was added to the United States Pharmacopoeia, which prompted major 
pharmaceutical companies like Lilly and Parke-Davis to develop extracts to be sold over the 
counter (Brecher, 1972). Cannabis had been considered an antispasmodic, analgesic, anesthetic, 
narcotic, and a powerful aphrodisiac. Additionally, it had been indicated to treat or alleviate 
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migraines, pain and discomfort of uterine afflictions, whooping-cough, gonorrhea, melancholia, 
neuralgia, and dysmenorrhea (Hollister, 2001; Potter, 1917). A meta-analysis examining studies 
dated from 1948-1998 found that in studies using cannabis, researchers reported the drug as 
effective for a variety of aliments: 70-93% of patients reported an antiemetic effect; 63-90% of 
patients reported increases in body weight and caloric consumption; and 60-97% of patients 
reported beneficial effects and reduction in spasticity (Hollister, 2001). 
Despite the evidence suggesting cannabis’ effectiveness as a medication, Congress began 
to pass laws prohibiting its use. Previously known as Indian cannabis, it has been speculated that 
cannabis’ association with Mexican immigrants led to the Pure Food and Drugs Act and the 
gradual prohibition of the drug (Gieringer, 1999). The Pure Food and Drugs Act was established 
in 1906 and identified cannabis as an intoxicating ingredient. As a result, all products that 
contained cannabis were required to mention the ingredient on the product’s label. Several years 
later, the Harrison Act of 1914 created a tax on the production and distribution of cocaine and 
opium. An earlier draft of the Harrison Act included a tax on cannabis, which was later dropped 
due to  its unpopularity with pharmaceutical manufactures (Gierigner, 1999). Eighteen years 
later, The Uniform Narcotic Drug Act (1932) was passed, which was the first federal legislation 
that explicitly mentioned cannabis in its text. The Uniform Narcotic Drug Act’s purpose was to 
encourage states to adopt laws in line with the Narcotic Import and Export Act of 1922, which 
limited the distribution of cocaine and opiates. The Uniform Narcotic Drug Act of 1932 
contained a provision that added the distribution of cannabis to other drugs including cocaine and 
opiates and called for penalties to include fines and imprisonment (Anslinger & Tompkins, 
1953). In 1937, the Marihuana Tax Act created cumbersome regulations and taxes and required 
individuals involved with the production, sale, or consumption of cannabis to register with the 
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federal government and pay a tax for each portion of the process. Each new law eroded cannabis’ 
status as a medical treatment until finally Congress passed the Controlled Substances Act of 
1970 (CSA). The CSA outlawed possession or distribution of drugs, classified cannabis as a 
Schedule I Drug (indicating it has a high potential for abuse and no medicinal value), imposed 
hefty fines and substantial imprisonment for selling and using cannabis, and created the Drug 
Enforcement Agency to ensure adherence to the law (Newton, 2013).  
Perhaps in response to the looming prohibition, shortly prior to the CSA passage 
recreational use of cannabis sharply increased (Reinarman, Nunberg, Lanthier & Heddleston, 
2011). In addition to the increase in recreational use, scientific interest increased as well; in 
1964, scientists discovered the chemical structure of the psychoactive ingredient in cannabis, 
delta-9 tetrahydrocannabinol (THC). This discovery fueled research into the potential for 
cannabis related treatment for various conditions, as well as its potential side effects (Reinarman 
et al., 2011). Although cannabis’ classification as a Schedule I substance by the CSA halted 
research in the United States, the research continued internationally. On the basis of continued 
empirical evidence of cannabis’ medicinal properties, California became the first state to pass a 
medicinal cannabis use law in 1996 (California Compassionate Use Act of 1996). The law, 
although counter to federal regulation, allowed for patients to use cannabis for medicinal 
purposes with a physician’s recommendation.  
Traditionally, medicinal cannabis has been considered a treatment for symptoms of 
serious and often terminal medical conditions like HIV/AIDS and cancer. A survey of patients in 
California using cannabis for medicinal purposes revealed this was no longer the case 
(Reinarman et al., 2011). Although physical ailments were among the most commonly cited 
benefits, mental health issues—including depression, anxiety and insomnia—were also among 
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the most commonly cited reasons for use. Moreover, the study found that 50.9% of the sample 
used cannabis as a substitute for prescription medication. The degree to which this increased 
usage represented sound medicinal practice or over-prescription is unclear. It is important, 
however, to consider that Reniarman et al. (2011) collected the information from for-profit 
evaluation clinics in California and therefore the data may not be representative of individuals 
who use cannabis without a medicinal card and cannot afford an evaluation for a medicinal 
cannabis card. 
Cannabis Use and Mental Health 
The existing literature on the relationship between cannabis use and mental health is 
inconclusive, although most researchers agree there is a relationship. The direction of the 
relationship, however, is difficult to identify as some studies have found benefits of cannabis use 
and others have found no relationship or detrimental effects (for a review, see Whiting et al., 
2015). THC has been linked to the release of dopamine, a neurotransmitter related to the 
noradrenergic system, which when dysregulated has been implicated in several mental health 
conditions (Carvalho & Van Bockstaele, 2012; Tanda, Pontieri, & Chiara, 1997). Several 
researchers have attempted to understand the nature of the relationship between cannabis use and 
mental health by using longitudinal data. McGee, Williams, Poulton, and Moffitt (2000) used 
longitudinal data from a birth cohort study in New Zealand to examine the relationship between 
cannabis use and mental health for individuals at ages 15, 18, and 21. The authors began 
collecting information on participants when they were 3, and again every two years until age 15, 
after which they followed-up at age 18 and 21; only data from ages 15, 18, and 21 were used in 
their study. The authors found that having a mental illness and reporting cannabis use at 15 was 
associated with coming from a family with low socioeconomic status, and that those who had a 
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mental illness at 15 were four times more likely to report cannabis use than those without a 
mental illness. They also found that using cannabis at age 15 did not predict mental health 
problems at 18, and that earlier cannabis use was not associated with an increased risk of a later 
anxiety disorder or depressive disorder. Further, mental health issues at 18 were predicted by 
having an earlier mental health issue, daily smoking and alcohol use, and low parental 
attachment. The authors suggested that the relationship between cannabis use and mental health 
reflected shared etiologies stemming from socio-economic disadvantage, behavior problems in 
childhood and low attachment to parents (McGee et al., 2000). The findings suggest mental 
health concerns may precede risk of cannabis use and that other systemic (e.g., socioeconomic 
status) and individual factors (e.g., age) may exacerbate the relationship between cannabis use 
and mental health issues. However, the study relied on a birth cohort from 1972-1973, which 
may not be representative of the current population, and used dated diagnostic criteria for mental 
health classifications that may not reflect current mental health standards.  
On the other end of the mental health spectrum, a recent review by Hahn (2018) 
examined the potential for treating cannabis users who experienced recent-onset of psychosis. 
Hanh (2018) reviewed the research that suggested individuals with schizophrenia who were 
cannabis abusers had a worse prognosis due to THC’s effect on psychotic symptoms and 
cognitive functioning. However, Hanh’s (2018) focus in the review was the effect of cannabidiol 
(CBD), a phytocannabinoid found in cannabis. Hahn found that unlike THC, CBD counteracted 
the effects of THC that contributed to the psychotic symptomology when the two were mixed, 
and that when CBD was isolated, it was found to alleviate psychotic symptoms in otherwise 
unmedicated individuals to a similar level as an antipsychotic medication. Although this review 
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provided evidence of the beneficial effects of cannabis, it focused on a specific cannabinoid that 
may not be available to all cannabis users.   
Fergusson, Horwood, and Swain-Campbell (2002) conducted a more statistically 
complex longitudinal study that incorporated frequency of use into their analyses. Fergusson and 
colleagues (2002) used data from a 1970’s New Zealand birth cohort that was collected yearly 
until age 16, with follow-ups at ages 18 and 21. The authors found that individuals who reported 
at least weekly cannabis usage (³ 51 times a year) had significantly increased rates of other illicit 
substance use, depression, suicide ideation, and suicide attempts. This relationship remained 
significant even after controlling for fixed-effects and time-varying effects. However, these 
outcomes varied with age such that younger users were more likely to experience these outcomes 
than older users, with the exception of depression for which the association did not vary with 
age. It should be noted however, that frequency of use intervals were determined by instances of 
use throughout the year and did not incorporate method of use (e.g., smoking vs. edibles) or 
amount used per instance (e.g., 1 joint vs. 5 joints). Additionally, similarly to the McGee and 
colleagues study (2000), this study used a birth cohort from the 1970s in New Zealand and used 
similarly dated measures for mental health classifications. Still, the Fergusson et al. (2002) 
finding that frequency of cannabis use was a significant predictor of suicidal ideation and 
depression across all age groups, and that age may differentially impact other outcomes suggests 
the relationship between cannabis use and mental health differs depending on the mental health 
concern.  
Generalized Anxiety Disorder and Cannabis 
Research on cannabis use and anxiety has mainly focused on social anxiety disorder (e.g., 
Buckner & Schmidt, 2009; Buckner & Zvolensky, 2014; Ecker & Buckner, 2018). As a result, 
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there is sparse research on generalized anxiety disorder (GAD) and cannabis use. The limited 
available research on the relationship between GAD and cannabis use is inconclusive and often 
contradictory, positing two opposing arguments (e.g., Kandel  et  al.1986; Kandel et al. 1992; 
Fergusson & Horwood  1997; McGee et al. 2000). The first of these theories suggests that the 
relationship between cannabis use and anxiety are causal, such that cannabis use can negatively 
affect or lead to the development of anxiety-related symptoms or anxiety disorders, in addition to 
other psychosocial problems. The opposing theory suggests that the relationship between 
cannabis use and anxiety is not causal and that the strong relationship is a result other factors that 
lead to the development of mental illness and initiation of cannabis use, with cannabis being 
commonly used as a coping mechanism  (Fergusson et al., 2002; Johnson & Kaplan, 1990). 
 Crippa and colleagues (2009) conducted a systematic literature review to understand the 
clinical, diagnostic, and causal implications of the relationship between cannabis use and 
anxiety. Their findings indicated that in infrequent or non-habitual users, cannabis can cause 
brief but intense episodes of anxiety, but regular users often reported a reduction of anxiety 
symptoms. When compared to non-users, frequent users displayed higher levels of anxiety with 
the severity of anxiety symptoms increasing with increased cannabis use (Crippa et al., 2009). It 
is important to note that the studies from which these findings came were published over 20 
years ago (e.g., 1998) and do not provide explanation of how classification of user status was 
determined.  
Crippa and colleagues (2009) found that participants who reported cannabis abuse or 
dependence also reported higher levels of anxiety. However, these findings were drawn from 
studies on adolescence, which can be a socially difficult developmental period, and from 
research on indigenous communities in northern Australia, which could have affected the 
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external validity of the studies. Still, the authors suggested the relationship between anxiety and 
cannabis use was dose dependent, whereby low doses may be beneficial as a treatment option 
and larger doses could result in the onset of anxiety-like symptoms. Further, the authors 
concluded that the evidence did not support that cannabis use alone was enough for the 
development of long-term anxiety but still suggested that cannabis use in conjunction with other 
risk factors may lead to the manifestation of anxiety disorders or anxiety-like symptomology 
(Crippa et al., 2009).  However, since a literature review cannot account for causal relationships, 
it is possible that those with increase anxiety symptoms chose to self-medicate (perhaps 
ineffectively) with cannabis. 
 Kedzior and Laeber (2014) conducted a meta-analysis to examine the relationship 
between anxiety and cannabis. The authors reviewed 31 studies, and included both longitudinal 
and cross-sectional studies in their analyses, highlighting a methodological limitation in the 
aggregation of datasets. Moreover, the studies collected by the authors spanned 10 countries 
(Australia, Canada, Columbia, France, Germany, Netherlands, New Zealand, Switzerland, UK, 
and US) and included participants from the general population, high school students, 
adolescents, and undergraduate students, further complicating the interpretation of the results by 
failing to parse out age groups and population sectors. The findings of this meta-analysis, which 
included 112,000 cases, indicated that cohorts with anxiety had a higher probability of using 
cannabis or having a comorbid cannabis use disorder. Additionally, despite not controlling for 
acute cannabis use, the results indicated that any level of cannabis use was positively related to 
clinically relevant symptoms of anxiety. It is important to note that studies evaluated in this 
meta-analysis that used symptom severity scales failed to show a positive association with only 
clinical symptoms of anxiety disorders producing this positive association between cannabis use 
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and anxiety disorders. The authors concluded that the small magnitude of the association 
between anxiety and cannabis use did not support a blanket prohibition of cannabis and noted 
that cannabis use was only a minor contributor to the worldwide disease burden (Kedzior & 
Laeber, 2014).    
Hayatbakhsh and colleagues (2007) took an alternative approach to understanding the 
relationship between cannabis use and anxiety and depression, and utilized data from a 
longitudinal study of pregnant women and their children initiated in 1981. Findings suggested 
that adolescents at the age of 14, whose mothers were diagnosed with anxiety or depression, 
smoked cigarettes, or consumed alcohol, had a higher risk of engaging in cannabis use at a later 
age. The authors also found that age of initiation and frequency of cannabis use were 
significantly associated with anxiety and depressive symptoms, such that those who used 
cannabis frequently were significantly more likely to report symptoms of anxiety and depression; 
this effect was greater with greater frequency of cannabis use and when initiation of use was 
early. Lastly, results indicated that the best predictors for cannabis use at age 21 were adolescent 
aggression/delinquency and cigarette use at age 14. Data for this study was generated from 
patients who were born in public hospitals in Australia, failing to capture those who were 
privately insured and likely of a higher socioeconomic status. Additionally, due to the survey 
design, psychosocial information was not collected at the age 14 and 21 follow-up, hindering the 
ability to determine the nature of psychosocial consequences on the relationship between 
cannabis use and anxiety and depression. Lastly, data on the initiation and frequency of cannabis 
use were both collected using self-report measures used only once, during the age 21 follow-up. 
The measures were unable to capture many individuals who used cannabis frequently but did not 
use other drugs. Moreover, the frequency of cannabis use was measured based on usage in the 
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past month, failing to account for periods in which cannabis was used more or less frequently 
than reported.   
Danielsson, Lundin, Agardh, Allebeck, and Forsell (2016) also conducted a longitudinal 
study attempting to identify a relationship between cannabis use, anxiety and depression. 
Danielsson and colleagues used data from a Swedish longitudinal cohort study with a three-year 
follow-up. Findings indicated those who used cannabis at baseline had a greater relative risk for 
depression and  anxiety at follow-up; however, this association was not statistically significant 
once confounding factors were added to the model. The authors concluded that cannabis use was 
not associated with depression or anxiety three years later. It is important to note that the sample 
consisted of participants from Sweden, where cannabis use may not be as prevalent as in the U.S. 
or other countries (Ter Bogt, Schmid, Nic Gabhainn, Fotiou, & Vollebergh, 2006) and as a result 
may limit generalizability. More importantly, the survey that was utilized in this study did not 
capture age of initiation or frequency of use. Additionally, between baseline and follow-up time 
points, the scale for anxiety was changed, potentially confounding results from the association.  
Impact of Sociodemographic Characteristics 
 The nature of the relationship between anxiety and cannabis use remains unclear and is 
only further complicated by the interaction with other sociodemographic factors, like gender.  
Research has consistently found that women have a significantly higher likelihood of developing 
an anxiety disorder when compared to men (Angst & Dobler-Mikola, 1985; Bruce et al., 2005). 
Hayatbakhsh and colleagues (2007) found that women were more likely to experience symptoms 
of anxiety by the age of 21. McGee and colleagues (2002) found that having a mental illness at 
the age of 18 was predicted by being female. Crippa and colleagues (2009) indicated that genetic 
factors that can contribute to anxiety in cannabis users may be enhanced for men. Further, out of 
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all anxiety disorders, GAD is the most common among women (De Dios et al., 2010). When 
cannabis is added to the relationship between anxiety and gender, it complicates the dynamic and 
understanding of the relationship.  
In the McGee et al. (2002) study that was previously mentioned, it was found that 
cannabis use at age 21 was strongly related to being a man, and cannabis use at the age of 18 
predicted having a mental health disorder at the age of 21, but only for men; this finding did not 
hold true for women. Patton and colleagues (2002) used longitudinal data from a 7-wave 
Australian cohort study and found that frequency of cannabis use was associated with anxiety 
and depression but only for women. Specifically, when compared to their male counterparts and 
non-users, young women who reported daily cannabis use were five times more likely to report 
depression and anxiety, and teenage girls who used cannabis on a weekly basis were two times 
more likely to report depression and anxiety. Additionally, De Dios and colleagues (2010) found 
that the relationship between cannabis use and anxiety in women was mediated by the 
expectation that cannabis would help with anxious symptoms (e.g., relieve stress and tension). 
Finally, Aspis and colleagues (2015) compared the quality of life (mental, physical and general) 
for three levels of usage, regular (at least weekly), occasional (less than weekly), and no use. 
They found that women who used cannabis to self-medicate had greater social and psychological 
problems when compared to men. Additionally, women who used cannabis regularly were more 
likely to endorse lower health-related quality of life items, more likely to report that emotional or 
physical problems interfered with social activities, and more likely to report that they 
accomplished less because of emotional problems when compared to non-users; these 
differences were not present for men. Taken together these findings speak to the potential 
importance of gender in the relationship between anxiety and cannabis use. 
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In addition to gender, various other sociodemographic factors have been implicated in the 
relationship between GAD and cannabis use. Specifically, Daniel et al. (2009) conducted a 
systematic review of the evidence associated with socioeconomic status and drug use and found 
that only cannabis use was predicted by lower childhood socioeconomic status. Low 
socioeconomic status has also been shown to predict manifestation of anxiety and anxiety-related 
symptoms at ages 15 and 21 (Miech, Caspi, Moffitt, Wright & Silva, 1999). Genetics have also 
been implicated in cannabis use, such that parental alcohol use predicted later cannabis use and 
anxious symptomology (Hayatbakhsh et al., 2007; Crippa et al., 2009).  
Lastly, cannabis use disorder must also be considered. Because cannabis use disorder 
represents a pathological problem with the use, abuse, or dependency of cannabis use and has 
been associated with higher rates of anxiety disorders (Kedzior & Laeber, 2014) it is important to 
consider its effect on GAD. Further, one of the symptoms of cannabis withdrawal is an increase 
of anxiety-like symptoms including nervousness, restlessness, and shakiness (Budney & Hughes, 
2006). These findings highlight the importance of the potential effect of cannabis use disorder on 
manifestation of GAD.  
This Study 
 Despite a lack of clear consensus on whether cannabis is beneficial or detrimental to the 
manifestation of GAD, studies have found that individuals report using cannabis for relief from 
symptoms related to anxiety (e.g., stress and insomnia) (Kedzior & Laeber, 2014; Martinez-
Rodrigues et al., 2008), with some individuals taking it instead of prescription medication 
(Reinarman et al., 2011), and that this expectation was a key moderator in the relationship 
between cannabis use and anxiety in women (De Dios, et al. 2010). However, the efficacy of 
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initiating or desisting from cannabis use as a treatment for anxiety has not been thoroughly 
studied.  
 This study aimed to examine how different cannabis use trajectories predict GAD status. 
Specifically, we aimed to understand how continuous use trajectories, switching use trajectories, 
or no use trajectories relate to the manifestation of GAD in a nationwide longitudinal study 
conducted in the United States. It was hypothesized that cannabis use trajectories would 
significantly predict meeting criteria for GAD.   
Method 
Participants 
Data used for this study was obtained from the National Epidemiologic Survey on 
Alcohol and Alcohol Related Conditions (NESARC; Chen, Yi, Dawson, Stinson & Grant, 2010). 
NESARC is a nationally representative longitudinal study that first began in 2001-2002. To 
generate a sample that was nationally representative, NESARC employed a multi-stage 
probability sampling design. The first step in this process consisted of creating and sampling 
primary sampling units (PSU) that were created through an automated process which grouped 
adjoining counties based on specified sociodemographic details. Relying on the Census 
2000/2001 Supplementary Survey and the Census 2000 Group Quarters Inventory sampling 
frame, the process produced a total of 2000 PSUs. Of the initial 2000 PSUs, PSUs with a 
population of 250,000 or more were selected, resulting in 655 selected PSUs. The remaining 
PSUs were then categorized in each state by sociodemographic characteristics and two PSUs 
from each category were selected, adding a total of 254 PSUs. These were then collapsed for a 
total of 435 PSUs (305 with populations over 250,000 and 130 of the remaining). Once 
completed, housing units were selected systematically with an intentional oversampling in Non-
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Hispanic Black and Hispanic housing units. In the final stage an individual in the housing unit 
was selected at random from a list of all home inhabitants over the age of 18 (Chen et al., 2010).  
The dataset for this study is the first longitudinal follow-up that began with data 
collection in July 2004 and ended in September 2005. NESARC initially conducted 43,093 face-
to-face interviews, and in wave 2 conducted 34,653 re-interviews from the initial population, 
yielding an 86.7% follow-up rate. Individuals not re-interviewed for wave 2 were not re-
interviewed due to institutionalization, death, deportation, mental or physical impairment, or 
active duty deployment (37.1%), and inability to locate or refusal to participate (62.9%). 
The majority of participants identified as White, (n = 20,161, 58.2% of the sample). 
There were more female participants (n = 20,089, 58%) than males (n = 14,564, 42%), and 
participants ranged in age from 20 to 89 (M = 49.06, s = 4.159); it should be noted that in wave 1 
age became cateogorical after 89, with participants 90 or above representing 0.8% of the sample 
at wave 2 (n = 276), for this reason we used age at wave 2. In terms of educational attainment, 
the most frequent response (n = 9,452, 27.3%) was obtaining a high school degree or a general 
equivalency degree (GED), and the most frequent earning bracket was between $20K and $50K 
(n = 12,976, 37.4%; see table 1 below).  
Ninety-four percent (n = 32,568) of the sample did not meet criteria for GAD, with the 
remaining sample meeting criteria for GAD in wave 1 only (n = 1,295, 3.7%), in wave 2 only (n 
= 1,210, 3.49%), or throughout both waves (n = 340, 0.98%).  Only 6.6% (n = 2,275) of the 
general sample reported cannabis use in either or both waves (see Table 2 and Table 3 below). 
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Table 1 
Socio-Demographic Descriptives by Gender  
Women % Men % Total % 
Age 
20-90 19,882 98.97% 14,495 99.53% 34,377 99.20% 
90+ 207 1.03% 69 0.47% 276 0.80% 
 
Ethnicity 
      
White 11,308 56.29% 8,853 60.79% 20,161 58.18% 
Black 4261 21.21% 2,326 15.97% 6,587 19.01% 
American Indian/Alaska Native 338 1.68% 240 1.65% 578 1.67% 
Asian/Native Hawaiian/Other Pacific Islander 542 2.70% 426 2.93% 968 2.79% 
Hispanic 3640 18.12% 2,719 18.67% 6,359 18.35% 
 
Personal Income 
      
No Income 6,898 34.34% 2,507 17.21% 9,405 27.14% 
Below Federal Poverty Line (>$13K) 1,207 6.01% 183 1.26% 1,390 4.01% 
$13K->$20K 2,833 14.10% 1,561 10.72% 4,394 12.68% 
$20K->$50K 6,811 33.90% 6,165 42.33% 12,976 37.45% 
$50K->$80K 1,747 8.70% 2,477 17.01% 4,224 12.19% 
$80K ->$100K 241 1.20% 620 4.26% 861 2.48% 
+100K 352 1.75% 1,051 7.22% 1,403 4.05% 
 
Educational Level 
      
No Formal Schooling 87 0.43% 57 0.39% 144 0.42% 
Did not complete middle school 791 3.94% 546 3.75% 1,337 3.86% 
Did not complete high school 2,371 11.80% 1,662 11.41% 4,033 11.64% 
Obtained HS diploma or GED 5,553 27.64% 3,899 26.77% 9,452 27.28% 
Did not complete college 4,355 21.68% 3,047 20.92% 7,402 21.36% 
Obtained associates or technical degree 2,043 10.17% 1,341 9.21% 3,384 9.77% 
Obtained bachelor’s degree 3,307 16.46% 2,630 18.06% 5,937 17.13% 
Obtained post-grad degree 1,582 7.87% 1,382 9.49% 2,964 8.55% 





GAD Status by Cannabis Use Status 




in Wave 1 
Only 
Cannabis Use in 
Wave 2 Only 
Cannabis Use in 
Wave 1 & 2 
Total 
No GAD 29,852 493 864 599 31,808 
GAD Throughout 301 5 17 17 340 
GAD in Wave 1 only 1,146 36 58 55 1,295 
GAD in Wave 2 only 1,079 29 57 45 1,210 
Total 32,378 563 996 716 34,653 
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Table 3             
              
Predictors by Gender             
  Women % Men % Total % 
Sought Mental Health Help SLI 
  
No 17,569 87.46% 13,673 93.88% 31,242 90.16% 
Yes 2520 12.54% 891 6.12% 3411 9.84% 
Sought Substance Use Help SLI  
No 19,972 99.42% 14,429 99.07% 34,401 99.27% 
Yes 117 0.58% 135 0.93% 252 0.73% 
Nicotine Dependence 
      
No 16,208 80.68% 10,888 74.76% 27,096 78.19% 
Yes 3881 19.32% 3676 25.24% 7557 21.81% 
History of Other Use Disorder 
No 13,107 65.24% 10,197 70.02% 23,304 67.25% 
Yes 6982 34.76% 4367 29.98% 11349 32.75% 
History of Family Addiction 
  
No 17,049 84.87% 12,811 87.96% 29,860 86.17% 
Yes 3040 15.13% 1753 12.04% 4793 13.83% 
History of Family Alcoholism 
No 13,107 65.24% 10,197 70.02% 23,304 67.25% 
Yes 6,982 34.76% 4367 29.98% 11349 32.75% 
Cannabis Use Disorder       
No 18,914 94.2% 12,638 86.8% 31,552 91.1% 
Yes 1,175 5.8% 1,926 13.2% 3,101 8.9% 
General Anxiety Disorder Status 
     
No GAD 18,552 92.35% 14,016 96.24% 32,568 93.98% 
GAD Throughout 160 0.80% 51 0.35% 211 0.61% 
GAD in Wave 1 392 1.95% 143 0.98% 535 1.54% 
GAD in Wave 2 985 4.90% 354 2.43% 1339 3.86% 
Cannabis Use Status 
      
No Use During Either Wave 19,192 95.53% 13,187 90.55% 32,379 93.44% 
Use in Wave 1 Only 254 1.26% 308 2.11% 562 1.62% 
Use in Wave 2 Only 391 1.95% 605 4.15% 996 2.87% 
Use During Both Waves 252 1.25% 464 3.19% 716 2.07% 
  
Measures 
 Sociodemographic variables included ethnicity, sex, past year personal income, age, 
educational level and family background items relating to addiction history, alcohol use, and 
cannabis use. 
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 NESARC employed the Alcohol Use Disorder and Associated Disabilities Interview 
Schedule-DSM-IV (AUDADIS-IV; Grant & Dawson, 2000), a structured diagnostic interview 
designed to be administered by laypeople. The AUDADIS-IV operationalized the Diagnostic and 
Statitistcal Manual version-IV (Americann Psychiatric Assocation, 2013) criteria for alcohol 
abuse and dependence, substance-specific abuse and dependence, mood disorders and anxiety 
disorders. The AUDADIS-IV includes an extensive list of symptom questions that operationalize 
criteria for drug-specific abuse and dependence for sedatives, tranquilizers, opiates (not 
including heroin or methadone), stimulants, hallucinogens, cannabis, cocaine, and 
inhalants/solvents, major depression, dysthymia, mania, hypomania, panic disorder (with and 
without agoraphobia), social phobia, specific phobia, and GAD.  For a more thorough review see 
Grant et al (2004).   
 Sociodemographic covariates. To control for the effect of sociodemographics, ethnicity, 
sex, and age were incorporated into the model. Highest completed education level and personal 
income in the past year were used to control for socioeconomic status by proxy. In the 
AUDADIS-IV, highest level of education was a 14-item categorical response set. For this study 
the 14 categories were collapsed into 8 items: 1 - No formal schooling; 2 – did not complete 
middle school; 3 – did not complete high school; 4 – obtained high school degree or GED; 5 – 
attended but did not complete college; 6 – obtained associates or technical degree; 7 – obtained 
bachelor’s degree; or 8- obtained post-grad degree. The obtained high school degree or GED 
group was selected as the reference group for the level of education as it represented the mode 
for the sample. Income for past year was collapsed from 17 items into 6 items: 1 – no income; 2 - 
below the federal poverty line (>$13k); 3 – earning above $13k but below $20k; 4 – earning 
above $20k but below $50k; 5 - earning above $50k but below $80k; 6 - earning above $80k but 
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below $100k; and 7 - above $100k. Below the federal poverty line was selected as the reference 
group for income level because it is the lowest of income levels and thus represents the lowest 
SES.  
Other substance use. Use of other substances including both illicit (e.g., amphetamines) 
and licit (e.g., cigarettes) drugs have been associated with cannabis use (Fergusson et al., 2002) 
and the manifestation of mental health issues (McGee et al., 2002; Hayatbakhsh et al., 2007). To 
control for the effect of other substance use, two variables were created: nicotine dependence and 
history of other substance use disorders. Nicotine dependence was created by combining wave 1 
diagnostic “lifetime nicotine dependence” and wave 2 diagnostic “nicotine dependence since last 
interview”. To address the history of other substance use disorders the wave 2 lifetime diagnostic 
classifications were used for alcohol abuse/dependence, sedative use disorder, tranquilizer use 
disorder, opioid use disorder, amphetamine use disorder, hallucinogen use disorder, 
inhalant/solvent use disorder, heroin use disorder, and other drug use disorder. Each variable was 
coded as absent (0) or present (1). 
Family history. History of family alcohol addiction was created by combining the 
responses to “In your judgment, has your blood or natural ______ been an alcoholic or problem 
drinker at ANY time in his/her life?” for father, mother, full brother, and full sister. History of 
family substance abuse history was similarly created, using the questions “In your judgment, has 
your blood or natural _____ had problems with drugs at ANY time in his/her life?” for father, 
mother, full brother, and full sister. Each variable was coded as absent (0) or present (1). 
 Mental health treatment. Because the dataset is longitudinal in nature, the possibility 
that participants sought help for mental health or substance use must be considered. To address 
the potential for seeking help with substance issues we used the question “since the last interview 
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did you seek help because of medicine or drug use?” The seeking help for mental health variable 
was created by combining seven versions of “since the last interview did you go to a 
counselor/therapist/doctor/psychologist/other person for help” for major depression, dysthymia, 
bipolar disorder, panic disorder and agoraphobia, social phobia, specific phobia, and GAD. Each 
variable was coded as absent (0) or present (1).  
 History of other disorders. GAD is often co-morbid with other disorders, to account for 
the effect of mood disorders, a variable was created for history of mood disorders. The 
AUDADIS-IV provides diagnostic classification for major depression, dysthymia, manic 
depression, and hypomanic disorder within their lifetime. The variable then was coded as absent 
(0) or present (1) for any of these diagnoses.  
 A variable was also created to account for the effect of anxiety disorders. Similar to the 
mood disorders, the diagnostic classifications for panic disorder with and without agoraphobia, 
agoraphobia, social phobia, and specific phobia were coded as absent (0) or present (1) to create 
this variable. 
 Cannabis use disorder. The AUDADIS-IV assesses cannabis use disorder as cannabis 
use dependency, cannabis abuse, or cannabis abuse and dependency for both waves. In wave 1, 
we used questions that asked whether the participant experienced the criteria for cannabis abuse, 
dependency or abuse and dependency during the last 12 months and prior to the last 12 months 
coded as absent (0) or present (1). In wave 2, questions that asked whether the participant 
experienced the criteria cannabis abuse, dependency, or abuse and dependency since the last 
interview or in their lifetime were also coded as absent (0) or present (1).  
 Target Variable: Cannabis use status. Cannabis use status trajectories consisted of four 
use categories: (a) cannabis use throughout (coded as 0); (b) cannabis use in wave 1 only (coded 
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as 1); (c) cannabis use in wave 2 only (coded as 2); and (d) no cannabis use throughout the study 
(coded as 3). This variable was created using the “did you use marijuana in the last 12 months 
only, before the last 12 months only, or during both periods,” question in wave 1, and the “used 
cannabis since last interview,” question in wave 2. Each of these variables was coded as absence 
(0) or presence of use (1). These scores were then used to determine participants’ cannabis use 
status trajectories. Where absence for both items resulted in no use throughout the study; 
presence for both items resulted in use throughout; and absence/presence patterns corresponding 
with waves 1 and 2 resulted in corresponding use status of use in wave 1 or wave 2, only.  
 Outcome variable: Generalized anxiety disorder (GAD). GAD status consisted of four 
GAD levels: (a) no GAD in either wave (coded as 0); b) GAD in wave 1 (coded as 1); c) GAD in 
wave 2 (coded as 2); and d) GAD throughout (coded as 3). This variable was created using the 
“generalized anxiety in the last 12 months illness-induced and substance-induced ruled out” 
diagnostic categorization in both waves, and the “generalized anxiety since last interview” 
diagnostic category from wave 2. Each of these variables was coded as absent (0) or present (1). 
These scores were then used to determine participants’ GAD status. Where absence for both 
items resulted in No GAD throughout, presence for both items resulted in GAD throughout, and 
absence/presence patterns corresponding with waves 1 and 2 resulted in corresponding GAD 
status in wave 1 and 2, only. 
Analytic Plan 
 Multinomial logistic regressions were performed to examine the association between  
GAD and cannabis use, including a null model with all controls, and a full model that included 
the target predictor, cannabis use status trajectories. Several covariates were included to control 
for confounding variables including ethnicity, sex, age, personal income for the past year, 
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educational level, history of other substance use disorder, cannabis use disorder, help sought for 
substance use since last interview, help sougnt for mental health since last interview, family 
addiction history, family mental health history, family alcohol abuse history and cannabis use 
status. Multinomial logistic regressions allow for comparisons of categorical comparisons (e.g., 
cannabis use status and GAD status) while controlling for the effect of other variables.  
Results 
 A multinomial logistic regression was run where the dependent variable of GAD status 
(No GAD throughout, GAD wave 1, GAD wave 2, or GAD throughout) was predicted by 
cannabis use status, while controlling for the effects of ethnicity, sex, past year personal income, 
educational status, family addiction and alcohol history, nicotine dependence, and cannabis use 
disorder. This model was then compared to a null model containing all predictors without the 
target variable. When compared to the null model, the cannabis model had a higher Akaike 
information criterion (13,422; 13,966, repectively); a higher Baysian information criterion 
(14,132; 14,752, respectively); a worse chi-square (χ2(81) = 5,214, p>.001; χ2(90) = 5,223, 
p>.001; respectively, p >.001); and a worse log likelihood (13,254; 13,780, respectively).). The 
model-fit and information criterion indicate that the null model is a better fit to the data than the 
full model which included cannabis use status as the outcome variable. The results are presented 
in tables 3, 4, and 5.  
 The multinomial logistic regression did not find support for the hypothesis. Initiation, 
continuance, or cessation of cannabis use did not significantly affect the odds ratio of 
progressing from not meeting criteria to meeting criteria for GAD throughout wave 1 and wave 2 
or exclusively in wave 1 or wave 2. This is consistent with results of the model comparison 
between the null model and cannabis use model, which showed that both models explain the 
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same amount of variance in the outcome and that the null model produced the lowest AIC, BIC, 
and log likelihood values. Overall, these results suggest the model of best fit would be the most 
parsimonious model, the null model, and that cannabis use was not a statistically meaningful 
predictor of GAD.    
Secondary Findings 
Sociodemographic covariates and various control variables were significant predictors at 
levels of GAD status. Sociodemographic covariates like ethnicity, education, and income level 
were significant only when comparing individuals who did not meet criteria for GAD throughout 
to individuals who only met criteria for GAD in wave 1 and wave 2. Specifically, individuals 
who were Hispanic (OR = 0.7225 [0.6026, 0.8663], Black (OR = 0.7989 [0.6716, 0.9504]), or 
Asian/Native Hawaiian had higher odds (OR = 0.5914 [0.3583, 0.9762) of having GAD in wave 
1 when compared to White participants. Although only significant in wave 1, the odds ratios 
were comparable at all levels of GAD status. In terms of income level, when compared to 
individuals who were earning below the federal poverty line, those who earned between $20K 
and $50K (OR = 0.8253 [0.7089, 0.9607]) and $50K and 80K (OR = 0.7749 [0.6176, 0.9721]) 
had higher odds of meeting criteria for GAD at wave 1 and participants who earned between 
$50K and $80K (OR = 0.7002 [0.5436, 0.9018]) had higher odds of meeting criteria for GAD at 
wave 2. Lastly, compared to participants who obtained a high school diploma or GED, 
participants who obtained a post-grad degree had a 1.331 higher odd ratio of meeting criteria for 
GAD at wave 1. These significant findings did not persist when comparing those that did not 
meet criteria for GAD throughout the study to those who did in wave 2 or throughout the study. 
 Each level of GAD status when compared to the reference group, no GAD throughout 
had different significant predictors. When compared to participants who did meet criteria for 
CANNABIS USE STATUS CHANGE AS A PREDICTOR OF GAD   26 
GAD throughout, participants who had a family history of addiction (OR = 1.3149 [1.0026, 
1.7245])  and sought help for substance use (OR = 2.138 [1.2056, 3.7915]) or mental health 
between waves had higher odds of meeting criteria for GAD throughout (OR = 2.0965 [1.8091, 
2.4295]). Participants who had a family history of alcoholism (OR = 1.2494 [1.0998, 1.4193]), 
history of mood (OR = 5.5467 [4.8773, 6.308]) or anxiety disorder (OR = 3.67 [3.2427, 
4.1536]), other substance use disorder (OR = 1.2956 [1.1313, 1.4838]), or sought mental health 
between waves (OR = 2.0965 [1.8091, 2.4295]) had higher odds of meeting criteria at wave 1 
when compared to participants who did not meet criteria for GAD throughout. Female 
participants had greater odds of meeting criteria for GAD at wave 1 (OR = 1.3761 [1.1981, 
1.5805]) and wave 2 (OR = 1.5557 [1.3449, 1.7996]). Participants who had a history of anxiety 
(OR = 1.3484 [1.1655, 1.56]) or mood disorders (OR = 1.7931 [1.5637, 2.0561]), had a nicotine 
dependence (OR = 0.6352 [0.5094, 0.7921]), had a different substance use diagnosis (OR = 
1.2335 [1.0676, 1.4252]) or sought mental health help (OR = 11.4722 [10.0834, 13.0523]) 
had higher odds of meeting criteria for GAD at wave 2 when compared to participants who did 
not meet GAD criteria throughout.  
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Table 3: Multinomial Logistic Regression Cannabis Model and Null Model 
 
No GAD Throughout compared to GAD Throughout Portion 
 Cannabis Model Null Model 
 OR (SE) Sig. OR (SE) Sig. 
GAD Throughout Intercept -7.0469 (0.4328) - -7.1158 (0.4261) - 
Sex 1.268 (0.1432) 0.097 1.2734 (0.1426) 0.090 
Hispanic 0.7963 (0.1796) 0.205 0.7968 (0.1795) 0.206 
Black 1.1008 (0.1644) 0.559 1.1006 (0.1643) 0.560 
American Indian/Alaska Native 0.9062 (0.3732) 0.792 0.9095 (0.3721) 0.799 
Asian/Native Hawaiian/Other Pacific Islander 0.9909 (0.482) 0.985 1.0052 (0.4808) 0.991 
White 0b - 0b - 
No Formal Schooling <.01  <.001* <.01 <.001* 
Did Not Complete Middle School 1.1545 (0.382) 0.707 1.1738 (0.3818) 0.675 
Did Not Complete High School 0.9998 (0.2072) 0.999 0.9945 (0.2071) 0.979 
Obtained Post-Grad Degree 1.3715 (0.2421) 0.192 1.3772 (0.242) 0.186 
Did Not Complete College 1.1087 (0.162) 0.524 1.1042 (0.1619) 0.540 
Obtained Associates or Technical Degree 1.1187 (0.2127) 0.598 1.1269 (0.2125) 0.574 
Obtained Bachelor’s Degree 0.8465 (0.2081) 0.424 0.8525 (0.2078) 0.443 
Obtained HS Diploma Or GED 0b - 0b - 
No Income 0.7729 (0.3034) 0.396 0.7755 (0.3032) 0.402 
$13K->$20K 0.9924 (0.1866) 0.967 0.9874 (0.1865) 0.946 
$20K->$50K 0.9275 (0.1463) 0.607 0.9335 (0.1461) 0.638 
$50K->$80K 0.7534 (0.2448) 0.248 0.754 (0.2444) 0.248 
$80K->$100K 0.5183 (0.6137) 0.284 0.5219 (0.6131) 0.289 
$100K+ 0.6463 (0.4548) 0.337 0.6626 (0.4538) 0.364 
Below Federal Poverty Line (>$13K) 0b - 0b - 
Family Addiction History 1.312 (0.1388) 0.0503* 1.3149 (0.1383) 0.048* 
Family Alcohol History 1.2625 (0.1274) 0.067 1.2698 (0.1272) 0.060 
History of Anxiety Disorders 4.3664 (0.1247) <.001* 4.3717 (0.1246) <.001* 
History of Mood Disorders 6.2244 (0.141) <.001* 6.1717 (0.1409) <.001** 
Nicotine Dependence 1.0303 (0.2683) 0.911 1.0184 (0.2675) 0.946 
Other Substance Use Diagnosis 1.0703 (0.1352) 0.615 1.0573 (0.1347) 0.679 
Cannabis Use Disorder 0.7261 (0.1734) 0.065 0.7702 (0.1659) 0.116 
DrugHelpSLI 2.2677 (0.3093) 0.008* 2.138 (0.2923) 0.009* 
SoughtMHHelpSLI 15.374 (0.132) <.001* 15.4781 (0.1318) <.001* 
Use During Both Waves 0.8519 (0.3072) 0.602 - - 
Use in Wave 1 Only 0.4808 (0.4803) 0.127 - - 
Use in Wave 2 Only 0.9088 (0.2861) 0.738 - - 
No Use During Either Wave 0b - - - 
a. The reference category is: No GAD. 
b. This parameter is set to zero because it is redundant. 
z      
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Table 4: Multinomial Logistic Regression Cannabis Model and Null Model 
 
No GAD Throughout compared to GAD at Wave 1 Portion 
 Cannabis Model  Null Model  
 OR (SE) Sig. OR (SE) Sig. 
GAD Wave 1 Intercept -4.6479 (0.2191) - -4.5986 (0.2141) - 
Sex 1.3842 (0.0708) <.001* 1.3761 (0.0707) <.001* 
Hispanic 0.7229 (0.0926) 0.001* 0.7225 (0.0926) <.001* 
Black 0.7986 (0.0886) 0.011* 0.7989 (0.0886) 0.011* 
American Indian/Alaska Native 0.9262 (0.198) 0.699 0.9285 (0.198) 0.708 
Asian/Native Hawaiian/Other Pacific Islander 0.5923 (0.2556) 0.041* 0.5914 (0.2557) 0.040* 
White 0b  0b  
No Formal Schooling 0.7906 (0.7262) 0.746 0.7865 (0.7262) 0.741 
Did Not Complete Middle School 0.9714 (0.1978) 0.883 0.9656 (0.1978) 0.860 
Did Not Complete High School 0.9652 (0.1073) 0.741 0.9646 (0.1072) 0.737 
Obtained Post-Grad Degree 1.3264 (0.1184) 0.017* 1.3305 (0.1183) 0.016* 
Did Not Complete College 0.8931 (0.0869) 0.194 0.8945 (0.0869) 0.199 
Obtained Associates or Technical Degree 1.0784 (0.1084) 0.486 1.0802 (0.1083) 0.476 
Obtained Bachelor’s Degree 0.9389 (0.0998) 0.527 0.9413 (0.0997) 0.544 
Obtained HS Diploma Or GED 0b  0b  
No Income 0.8628 (0.1552) 0.342 0.8613 (0.1553) 0.336 
$13K->$20K 0.8752 (0.1002) 0.184 0.8732 (0.1002) 0.176 
$20K->$50K 0.8288 (0.0776) 0.016* 0.8253 (0.0775) 0.013* 
$50K->$80K 0.7788 (0.1158) 0.031* 0.7749 (0.1157) 0.028* 
$80K->$100K 0.7678 (0.2305) 0.252 0.7588 (0.2304) 0.231 
$100K+ 0.9798 (0.1798) 0.910 0.9728 (0.1796) 0.878 
Below Federal Poverty Line (>$13K) 0b  0b  
Family Addiction History 1.0716 (0.0776) 0.373 1.0759 (0.0775) 0.345 
Family Alcohol History 1.2501 (0.0651) 0.001* 1.2494 (0.0651) 0.001* 
History of Anxiety Disorders 3.6782 (0.0632) <.001* 3.67 (0.0632) <.001* 
History of Mood Disorders 5.5352 (0.0657) <.001* 5.5467 (0.0656) <.001* 
Nicotine Dependence 0.9354 (0.1402) 0.634 0.9231 (0.1399) 0.567 
Other Substance Use Diagnosis 1.2877 (0.0695) <.001* 1.2956 (0.0692) <.001* 
Cannabis Use Disorder 0.8671 (0.0985) 0.148 0.8489 (0.0927) 0.077 
DrugHelpSLI 1.2663 (0.2497) 0.344 1.348 (0.2441) 0.221 
SoughtMHHelpSLI 2.0917 (0.0753) <.001* 2.0965 (0.0752) <.001* 
Use During Both Waves 1.1071 (0.1701) 0.550 - - 
Use in Wave 1 Only 0.9913 (0.1941) 0.964 - - 
Use in Wave 2 Only 1.237 (0.1543) 0.168 - - 
No Use During Either Wave 0b  - - 
a. The reference category is: No GAD. 
b. This parameter is set to zero because it is redundant. 
z     
nn 
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Table 5: Multinomial Logistic Regression Cannabis Model and Null Model 
 
No GAD Throughout compared to GAD at Wave 2 Portion 
 Cannabis Model  Null Model  
 OR (SE) Sig. OR (SE) Sig. 
GAD Wave 2 Intercept -4.5473 (0.2167) - -4.4516 (0.2113) - 
Sex 1.569 (0.0745) <.001* 1.5557 (0.0743) <.001* 
Hispanic 0.9066 (0.0889) 0.270 0.9073 (0.0889) 0.274 
Black 1.1014 (0.0834) 0.246 1.1035 (0.0833) 0.237 
American Indian/Alaska Native 1.0061 (0.2187) 0.978 1.0118 (0.2185) 0.957 
Asian/Native Hawaiian/Other Pacific Islander 0.9115 (0.2284) 0.685 0.9142 (0.2284) 0.694 
White 0b  0b  
No Formal Schooling 1.5658 (0.4453) 0.314 1.5537 (0.4452) 0.322 
Did Not Complete Middle School 1.1604 (0.1827) 0.416 1.1493 (0.1827) 0.446 
Did Not Complete High School 1.1834 (0.107) 0.116 1.1877 (0.1069) 0.108 
Obtained Post-Grad Degree 1.0511 (0.1399) 0.722 1.0554 (0.1398) 0.700 
Did Not Complete College 1.0913 (0.089) 0.326 1.0977 (0.089) 0.295 
Obtained Associates or Technical Degree 1.1754 (0.1138) 0.156 1.1755 (0.1138) 0.155 
Obtained Bachelor’s Degree 1.0833 (0.1023) 0.435 1.0877 (0.1023) 0.411 
Obtained HS Diploma Or GED 0b  0b  
No Income 0.9269 (0.153) 0.620 0.9245 (0.153) 0.608 
$13K->$20K 0.9484 (0.1019) 0.604 0.9452 (0.1019) 0.580 
$20K->$50K 0.9546 (0.079) 0.557 0.9493 (0.0789) 0.510 
$50K->$80K 0.7075 (0.1292) 0.007* 0.7002 (0.1291) 0.006* 
$80K->$100K 1.0421 (0.2313) 0.859 1.0278 (0.231) 0.906 
$100K+ 0.8551 (0.2045) 0.444 0.8419 (0.2044) 0.400 
Below Federal Poverty Line (>$13K) 0b  0b  
Family Addiction History 1.0097 (0.0854) 0.910 1.0174 (0.0853) 0.840 
Family Alcohol History 1.1167 (0.068) 0.105 1.1123 (0.068) 0.118 
History of Anxiety Disorders 1.3529 (0.0744) <.001* 1.3484 (0.0744) <.001* 
History of Mood Disorders 1.7813 (0.07) <.001* 1.7931 (0.0698) <.001* 
Nicotine Dependence 0.6441 (0.1129) <.001* 0.6352 (0.1126) <.001* 
Other Substance Use Diagnosis 1.2137 (0.0741) 0.009* 1.2335 (0.0737) 0.004* 
Cannabis Use Disorder 0.9864 (0.1131) 0.903 0.9286 (0.1077) 0.491 
DrugHelpSLI 1.1527 (0.2269) 0.531 1.278 (0.2197) 0.264 
SoughtMHHelpSLI 11.4724 (0.0659) <.001* 11.4722 (0.0658) <.001* 
Use During Both Waves 1.3072 (0.1869) 0.152 - - 
Use in Wave 1 Only 1.2947 (0.2137) 0.227 - - 
Use in Wave 2 Only 1.2499 (0.1566) 0.154 - - 
No Use During Either Wave 0b  - - 
a. The reference category is: No GAD. 
b. This parameter is set to zero because it is redundant. 
z     
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Discussion 
 The current study aimed to address the ongoing debate about the relationship between 
cannabis use and anxiety by specifically focusing on GAD. The study sought to answer whether 
meeting criteria for GAD could be significantly affected by initiation, continuation, or cessation 
of cannabis use in a nationally representative longitudinal sample. Findings suggested cannabis 
use did not significantly predict or affect meeting criteria for GAD throughout the study, or in 
wave 1 or wave 2 exclusively. When the full model was compared to the null model, the full 
model with the cannabis use covariates did not account for any additional variance, and yielded 
the worse model fit estimates, suggesting the best fitting and most parsimonious model would be 
the null model.  
Failure to find significant results for the hypothesis has several implications. Primarily, 
the finding that different cannabis use trajectories did not significantly predict GAD status 
suggests that initiation, continuance, or cessation of cannabis use may not increase the odds of 
meeting criteria for GAD within a 3-year period differently than for those participants who did 
not use at all during the study. Additionally, the lack of significant findings can ameliorate fears 
that decriminalizing cannabis use will lead to an increase in individuals developing GAD. 
Although the effects of the initiation of cannabis use and risk factors have been studied in the 
past, different research methods and updated diagnostic criteria have affected the quality and 
validity of previous research. Future research should seek to examine how predictors of cannabis 
initation and use are related to predictors of GAD status.  
Despite failing to find support for the hypothesis, several significant secondary 
relationships were found. There were three predictors that remained significant at all levels of 
GAD when compared to particpants who did not have GAD throughout: history of mood 
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disorder, history of anxiety disorder, and seeking help for mental health. The mood and anxiety 
disorders evaluated in this study were: major depression, dysthymia, manic depression, 
hypomanic disorder, panic disorder with and without agoraphobia, agoraphobia, social phobia, 
and specific phobia. The finding that history of mood or anxiety disorders was a significant 
predictor of GAD status for participants is consistent with previous findings highlighting 
comorbidity between these anxiety and mood disorders (Byers, Yaffe, Covinsky, Friedman, & 
Bruce, 2010). The finding that seeking help for mental health between waves was a significant 
predictor for all levels of GAD is consistent with research on expectancy theory. Expectancy 
theory suggests that individuals become more anxious when they anticipate anxiety or as a result 
of the fear of anxiety (Taylor, Koch, & McNally, 1992). These findings may be explained by the 
expectancy theory relating to seeking help for mental health. Future research should further 
examine the role of anticipating anxiety in cannabis use and on the presentation of GAD. 
The remaining covariate relationships were not significant predictors at each level of 
GAD.  Sex was a significant predictor of meeting criteria for GAD at wave 1 and 2, such that 
women had higher odds of meeting criteria for GAD. This finding is consistent with research 
findings that indicate women experience anxiety disorders at a higher frequency than men 
(Angst, & Dobler-Mikola, 1985; Bruce et al, 2005). Other substance use and familial substance 
use were also significant predictors. When compared to participants who did not meet criteria for 
GAD throughout the study, family history of alcohol abuse was a significant predictor of 
meeting criteria for GAD throughout and family addiction history was a significant predictor of 
meeting criteria for GAD at wave 1. This finding is consistent with research that has found 
history of family addiction or alcoholism were key factors in the presence or absence of various 
disorders, including anxiety and mood disorders (Milne et al., 2009; Hayatbakhsh 2007). 
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Participants who engaged in other substance use at wave 1 or wave 2 had higher odds of meeting 
criteria for GAD when compared to those who did not meet criteria throughout. Additionally, 
participants who reported nicotine dependence had higher odds of meeting criteria for GAD at 
wave 2 when compared to participants who did not have GAD throughout. These findings are 
consistent with studies that have found other substance use and nicotine use is associated with 
higher risk of having anxiety or experiencing anxiety-related symptoms (Hayatbakhsh 2007). 
 This study’s use of archival data presented several limitations. Primarily, the data was 
collected between 2001-2002 and 2003-2004, representing a 3-year span. It is possible that a 
longer timeframe or more frequent intervals may have resulted in better dectection and testing of 
the relationship between cannabis use and GAD diagnosis. Further, research has found that the 
relationship between cannabis use and GAD may be dose dependent (Crippa et al., 2009). 
However, the dataset did not include information on how consistently cannabis was used, and 
determined frequency based on instances of use, creating a limitation on the analyses that could 
be conducted. Future studies should use a controlled experiment design to understand the 
relationship between initation and use of cannabis and how its frequency and consistency of use 
are related to meeting criteria for GAD. Future studies should also further examine how different 
usage frequencies affect whether cannabis is an effective treatment for GAD, if at all.  
The use of NESARC data presented other limitations for this study. NESARC is a three-
wave study, however, during the time between wave 2 data collection ending and wave 3 data 
collection starting, the diagnostic and statistical manual had been revised from version 4-TR to 
version 5 (American Psychiatry Association, 2013). Data collected in wave 1 and 2 are no longer 
aligned with the diagnostic categories in the newest version, which limited generalizeability. 
Additionally, NESARC collected cannabis use data using a self-report measure, which has been 
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shown to suppress reporting due to the sensitivity of the topic (Van der Linden, 2017), perhaps as 
a result only a small subset of the sample reported using cannabis. The sample subset of 
participants who met criteria for GAD was also small. The small sample sizes were compared to 
larger sample sizes (e.g. No GAD) and may not be statistically representative of relationship 
between individuals who engage in cannabis use and meet criteria for GAD. However, it is 
important to note that there was great variability in the samples sociodemographic information 
(e.g. age, income level, education level, and ethnicity) as a result of NESARC’s nationally 
representative sample. Lastly, the NESARC cohort represents individuals who were born in 1915 
through 1985, during this timeframe cannabis use was available over-the-counter, was 
criminalized, and has recently begun to become decriminalized. This cohort, although currently 
representative, may not reflect the change in social attitudes toward the use of cannabis, and may 
not reflect the impact of the changes in legislation. Future research should collect data from a 
later birth cohort and compare cannabis use trends to understand the impact of the cohort effect 
on cannabis use.  
The finding that cessation or initiation of cannabis use during a 2-year period does not 
increase or decrease the likelihood of meeting criteria for GAD has several implications. 
Primarily, these findings add evidence against the theory that there is a cause and effect 
relationship between GAD and cannabis use. Additionally, these findings serve to ameliorate 
concerns that increased legalization would lead to an increase in rates of GAD. Despite the 
limitations, this study contributes research to an area that needs further exploration, the 
relationship between GAD and cannabis use, during a time in which the information can be 
directly utilized to make informed decisions. 
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